Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Biogen Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Biogen Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses: Biogen Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Rating Financials

Biogen Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Biogen Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Biogen Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Biogen Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Biogen Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
24.12B
AA
75.21B
A
61.16B
BBB
58.53B
AA
56.54B
AA
20.85B
AA
19.91B
AAA
18.8B
CCC
16.34B -
A
- -
14.7B -
BB
- -
Average 36.62B
A
Weighted average by Cap.
A
See all sector ratings